Response by Lee and Ovbiagele to Letter Regarding Article, “Pioglitazone for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Liraglutide, semaglutide, and empagliflozin are antidiabetic drugs that have been proven in randomized controlled trials to have a beneficial effect at reducing the composite primary end point of major cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death).1–3 The benefits of long-acting glucagon-like peptide 1 (GLP-1) receptor agonists, such as liraglutide and semaglutide, are perhaps related to the modified progression of atherosclerotic vascular disease,4 whereas benefits of sodium-glucose cotransporter 2 (SGLT-2) inhibitors, such as empagliflozin, may be more closely linked to hemodynamic changes. These differences in postulated mechanisms of action may explain, …